达格列净治疗慢性肾脏病的成本效果:DAPA-CKD的健康经济学分析
本研究基于DAPA-CKD试验构建终身Markov模型,从英国、德国和西班牙付费方视角评估达格列净治疗CKD的成本效果。达格列净使eGFR 15-89 ml/min per 1.73 m2范围时间延长1.7年,生命 expectancy延长1.7年,QALY增益0.82至1.00,增量成本效果比分别为8280、17623和11687美元,低于意愿支付阈值。
要点
- 达格列净使eGFR 15-89 ml/min per 1.73 m2范围时间延长1.7年(95%可信区间0.8至2.4)。
- 未贴现生命 expectancy延长1.7年(95%可信区间0.7至2.5)。
- QALY增益0.82至1.00,ICER在英国、德国和西班牙分别为8280、17623和11687美元。
核心结论
- 在符合DAPA-CKD试验入选要求的患者中,达格列净在英国、德国和西班牙卫生保健系统内可能具有成本效果。
研究设计与样本
- 基于DAPA-CKD试验构建终身Markov模型,健康状态由eGFR水平和KRT类型定义。
- 从英国、德国和西班牙付费方视角评估达格列净联合标准治疗的成本效果。
- 直接医疗成本和效用值分别来源于已发表文献和DAPA-CKD试验。
- 成本和获益在英国按每年3.5%贴现,在德国和西班牙按3%贴现。
主要发现
- 达格列净组在eGFR 15-89 ml/min per 1.73 m2范围的时间为12.1年(95%可信区间8.9至14.1),标准治疗组为10.4年(95%可信区间7.7至12.4),达格列净组延长1.7年(95%可信区间0.8至2.4)。
- 达格列净组未贴现生命 expectancy为15.5年(95%可信区间11.1至18.2),标准治疗组为13.8年(95%可信区间9.9至16.5),达格列净组延长1.7年(95%可信区间0.7至2.5)。
- 贴现QALY增益为0.82(95%可信区间0.38至1.18)至1.00(95%可信区间0.46至1.41)。
- 增量成本效果比在英国为8280美元,德国为17623美元,西班牙为11687美元。
关键数值与推荐
- 意愿支付阈值:英国每QALY 27510美元,德国和西班牙每QALY 35503美元。
- 在英国、德国和西班牙,达格列净的增量成本效果比均低于上述意愿支付阈值,表明具有成本效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: CKD imposes a significant burden on patients and health care providers, particularly upon reaching kidney failure when patients may require KRT. The Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD) trial demonstrated that dapagliflozin, with standard therapy, reduced CKD progression and KRT requirement. The study objective was to estimate the cost-effectiveness of dapagliflozin for the treatment of CKD from payer perspectives in the United Kingdom, Germany, and Spain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We constructed a lifetime Markov model to characterize outcomes in patients with CKD on the basis of the DAPA-CKD trial. Health states were defined by eGFR level and KRT type. Direct health care costs and utility values were sourced from published literature and the DAPA-CKD trial, respectively. Costs and benefits were discounted at 3.5% per annum in the United Kingdom and 3% in Germany and Spain. RESULTS: In patients eligible for the DAPA-CKD trial, treatment with dapagliflozin was predicted to reduce rates of CKD progression, with patients predicted to spend 1.7 (95% credibility interval, 0.8 to 2.4) more years in the eGFR range 15-89 ml/min per 1.73 m2 versus standard therapy alone (12.1; 95% credibility interval, 8.9 to 14.1 versus 10.4; 95% credibility interval, 7.7 to 12.4 years). Life expectancy (undiscounted) was correspondingly predicted to increase by 1.7 (95% credibility interval, 0.7 to 2.5) years (15.5; 95% credibility interval, 11.1 to 18.2 versus 13.8; 95% credibility interval, 9.9 to 16.5 years). This in addition to reduced incidence of adverse clinical outcomes, including hospitalization for heart failure, resulted in modeled quality-adjusted life year (discounted) gains between 0.82 (95% credibility interval, 0.38 to 1.18) and 1.00 (95% credibility interval, 0.46 to 1.41). These gains translated to incremental cost-effectiveness ratios of $8280, $17,623, and $11,687 in the United Kingdom, Germany, and Spain, respectively, indicating cost-effectiveness at willingness-to-pay thresholds (United Kingdom: $27,510 per quality-adjusted life year; Germany and Spain: $35,503 per quality-adjusted life year). CONCLUSIONS: In patients meeting the eligibility requirements for the DAPA-CKD trial, dapagliflozin is likely to be a cost-effective treatment within the UK, German, and Spanish health care systems. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Dapagliflozin and Prevention of Adverse Outcomes in CKD (DAPA-CKD), NCT03036150.
引用
- McEwan P, Darlington O, Miller R, et al. Cost-Effectiveness of Dapagliflozin as a Treatment for Chronic Kidney Disease: A Health-Economic Analysis of DAPA-CKD. Clin J Am Soc Nephrol. 2022. PMID: 36323444. doi:10.2215/CJN.03790322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。